Trial Profile

A single-center prospective study of Tix-Cil in preventing SARS-CoV-2 infection in RTX-treated ARD patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cilgavimab/tixagevimab (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

23 Jul 2024 New trial record
15 Jun 2024 Results (Between October and December 2022) assessing the efficacy and safety of Tix-Cil in preventing SARS-CoV-2 infection in RTX-treated ARD patients, presented at the 25th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com